Clinical Trial Update: A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD. [Phase 2, Phase 3]

View source ↗

Summary

A completed phase 2/3 trial evaluating different doses of pegaptanib sodium versus sham in wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Eyetech Pharmaceuticals | Conditions: Age-Related Macular Degeneration | Phase 2, Phase 3 | Status: COMPLETED